Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Noreen Palinkas
Articles
Current and Future Considerations for Oncology Biosimilars in 2020
December 28th 2019The US health care system expects 2020 to be a year of major cost savings, in part because of the projected significant traction from 3 major biosimilars for rituximab (Rituxan), bevacizumab (Avastin), and trastuzumab (Herceptin), which accounted for a total of $19.4 billion in sales in 2018.
Read More
Latest Updated Articles
Published: October 23rd 2024 | Updated: October 24th 2024
What to Know About E Coli Outbreak Linked to McDonald’s Quarter Pounders
Published: January 18th 2016 | Updated: October 18th 2024
10 Pharmacy Quotes That Will Make You Rethink the Profession
Published: September 22nd 2015 | Updated: October 14th 2024
Gabapentin Differs From Pregabalin in Several Key Ways
Published: August 30th 2024 | Updated: November 21st 2024
Congress Requests Corrections to Testimony From Three Largest Pharmacy Benefit Manager Executives Following FTC Report
Published: October 8th 2024 | Updated: November 21st 2024
What Drug Rates Are Reported in Price Transparency Data?
Published: October 7th 2024 | Updated: November 21st 2024
What Went Wrong: How Formularies, Contracts, and Rebates Created a Headwind for Biosimilars
